Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Digoxin + LOXO-435 + Midazolam + Rosuvastatin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Digoxin | Cardoxin | Digitalis Glycoside | ||
| LOXO-435 | LOXO 435|LOXO435|LY3866288|LY 3866288|LY-3866288|Vepugratinib | FGFR3 Inhibitor 21 | LOXO-435 is an isoform-selective inhibitor of FGFR3 with potential antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT119). | |
| Midazolam | Dormicum | Dea No. 2884 | ||
| Rosuvastatin | Astende | ZD-4522 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05614739 | Phase I | Enfortumab vedotin-ejfv + LOXO-435 + Pembrolizumab LOXO-435 Digoxin + LOXO-435 + Midazolam + Rosuvastatin LOXO-435 + Trastuzumab deruxtecan | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1) | Recruiting | USA | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 3 |